Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Evelo Biosciences Inc EVLO

Healthcare Biotechnology
Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. It has built a platform to discover and develop oral medicines, which target the small intestinal axis (SINTAX). Its product candidates are pharmaceutical preparations of single... see more

Recent & Breaking News (GREY:EVLO)

Evelo Biosciences Announces Grant of Inducement Award

GlobeNewswire September 1, 2022

Evelo Biosciences to Participate in Morgan Stanley 20th Annual Global Health Care Conference

GlobeNewswire September 1, 2022

Evelo Biosciences Announces Succession Plan

GlobeNewswire August 11, 2022

Evelo Biosciences Announces Second Quarter 2022 Financial Results and Business Highlights

GlobeNewswire August 11, 2022

Evelo Biosciences to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022

GlobeNewswire August 5, 2022

Evelo Biosciences Announces Appointment of Marella Thorell as Chief Financial Officer

GlobeNewswire July 18, 2022

Evelo Biosciences Announces $79.2 Million Registered Direct Offering of Common Stock

GlobeNewswire May 25, 2022

CORRECTION: Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights

GlobeNewswire May 12, 2022

Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights

GlobeNewswire May 12, 2022

Evelo Biosciences Appoints John Maraganore, Ph.D. and Tassos Gianakakos as Strategic Advisors

GlobeNewswire April 21, 2022

Evelo Biosciences Provides Updated Guidance on Advancing Clinical Inflammation Programs

GlobeNewswire April 14, 2022

Evelo Biosciences Announces Appointments of Jose-Carlos Gutiérrez-Ramos and Tonya Williams to Board of Directors

GlobeNewswire April 6, 2022

Evelo Biosciences Presents Late-Breaking Oral Abstract on Data from Phase 2 Trial of EDP1815 in Psoriasis at 2022 American Academy of Dermatology Annual Meeting

GlobeNewswire March 26, 2022

Evelo Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

GlobeNewswire March 24, 2022

Evelo Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022

GlobeNewswire March 17, 2022

Evelo Biosciences to Host KOL Discussion on Treatment Advances for All Stages of Psoriasis and Potential of SINTAX Medicines

GlobeNewswire March 7, 2022

Evelo Biosciences to Participate in Cowen 42nd Annual Health Care Conference

GlobeNewswire March 2, 2022

Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs

PR Newswire February 28, 2022

Durable and Deepening Clinical Responses Observed in Post-Treatment Period of Evelo Bioscience's Phase 2 Clinical Trial of Oral EDP1815 in Psoriasis

GlobeNewswire February 28, 2022

Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis

GlobeNewswire February 17, 2022